Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early MMR vaccination at 6 months in infants
2016-001901-18Phase 4Completed
- Sponsor
- Rigshospitalet
- Start
- Oct 2016
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4 trial of M-M-R II in measles, mumps and rubella (2 arms), sponsored by Rigshospitalet. Primary endpoint: Primary: measles neutralising antibody level 1 month after experimental MMR vaccination at 6 months. Started Oct 2016; status: completed.
02
Drugs
M-M-R II
03
Conditions
measlesmumpsrubella
Beyond the preview
Go deeper on 2016-001901-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001901-18.